Introduction
Myocardial ATP-sensitive potassium (KATP) channels are closed during physiological conditions but are activated by a decrease in intracellular ATP-concentration (Noma 1983) . KATP activation during myocardial ischemia postpones the onset of irreversible damage, and reduces the size of the area of myocardial infarction (reviewed by Schotborgh and Wilde 1997) . Blockade of KATP channels by sulfonylurea antagonists and sodium 5-hydroxvdecanoate (5-HD) reverses these cardioprotective effects (Schotborgh and Wilde 1997) . The exact mechanism of cardioprotection by KATP activation has not yet been unravelled. Shortening of action potential duration due to the opening of KATP channels (Shaw and Rudy 1997, Wilde 1997) , the previously supposed underlying mechanism, is not a prerequisite for cardioprotection to occur (Yao et al. 1994) . Mitochondrial KATP channels may play a role, but further studies are needed for clarification (Szewczyck 1997) .
Another potential contributing mechanism involves KATP channels in cardiac sympathetic nerve-endings. Throughout the central nervous system, KATP channels are located on both pre-and postsynaptic neurones (Mourre et al. 1990 ). Release of neurotransmitters in the brain can be influenced by neuronal KATP modulation, both under normoxic and ischemic-like conditions (Amoroso et al. 1990 , Zini et al. 1993 ). Oe and colleagues show a relationship between KATP modulation and norepinephrine release from the atrium under physiological conditions (Oe et al. 1999) . To correctly interpret their results and appreciate the potential role of KATP channels in catecholamine release modulation during myocardial ischemia, understanding of the mechanisms of catecholamine secretion during physiological and pathophysiological conditions is essential.
2. Catecholamine release, uptake and metabolism in the normal heart In the sympathetic nerve terminals, norepinephrine (NE) is contained in granular storage vesicles. Activation of the sympathetic nerve fibres leads to influx of calcium through voltage-gated calcium channels and subsequent calcium-dependent exocytotic release of NE from the vesicles into the extracellular space ( Figure 1A ) (Knight et al. 1989) .
Secreted NE can influence further NE release from the nerve ending via activation of presynaptic alpha-adrenoceptors (inhibitor,' effect) and beta-adrenoceptors (facilitatory effect). Furthermore, activation of postsynaptic adrenoceptors by NE has a positive inotropic and chronotropic effect. Excess NE may be removed from the extracellular space by three different mechanisms: (1) re-uptake into the nerve terminal from where it was originally secreted (uptake-1); (2) diffusion of NE into the surrounding body fluids K AT p and noradrenaline release and tissues (uptake-2); (3) breakdown of NE extracellularly by the enzyme catechol-0-methyl transferase (COMT). Uptake-1 is an active carrier-mediated, sodium-dependent transport process capable of removing large amounts of secreted NE from the extracellular space back into the nerve terminal (Paton 1976) . During physiological conditions, the high extracellular sodium concentration as opposed to inside the nerve terminal ensures that carrier-mediated NE transport is almost exclusively inward (Sammet and Graefe 1979) .
Besides its regulation by presynaptic adrenoceptors, NE release is inhibited by activation of presynaptic muscarinic acetylcholine receptors and Al adenosine receptors (Fuder 1985) . In addition, recent reports have shown a possible regulatory role for neuronal ATP-sensitive potassium channels (Amoroso et al. 1990 , Zini et al. 1993 , Ye et al. 1997 . Oe and colleagues (1999) describe an inhibitor} 7 effect of cromakalim, a KATP channel opener, on the stimulation-evoked NE-release from the isolated guinea pig, but not human, atrium. This effect was antagonised by the addition of glibenclamide, a KATP channel blocker, suggesting the involvement of the channel. In addition, glibenclamide alone increased both resting and stimulation-evoked NE release. However, since glibenclamide is not a specific K.VIP channel blocker and since high concentrations of both the KATP blockers and openers were necessary for the mentioned effects, it remains unclear whether the observed effects are a direct result of modulation of the channel. The more specific KATP channel antagonist 5-hydroxydecanoate (5-HD) did not influence stimulation-evoked NE-release, making a direct involvement of the KATP channel more questionable. However, as suggested by the authors, the possibility of selectivity of 5-HD for mitochondrial rather than plasmalemmal channels remains. In addition, molecular heterogeneity of KATP channels may lead to pharmacological diversity, which may also explain the observed paradoxical increase in NE release due to pinacidil (Oe et al. 1999 , Takata et al. 1992 ), a compound with KATP activating properties in vascular smooth muscle and pancreas. It is of interest that the effects of KATP modulation observed by Oe and colleagues in the guinea pig atrium were attenuated in human atria. In particular, KATP channel opening did not affect exocytotic NE release. Since these tissues were obtained from patients suffering from cardiovascular disease, it is possible that due to chronic ischemia in these patients, the open state, the number of available channels, or the responsiveness of these channels was altered.
Catecholamine release during myocardial ischemia/infarction
During myocardial ischemia, local norepinephrine accumulation in the myocardium may occur as a result of exocytotic or non-exocytotic release from sympathetic nerve-endings.
Reflex stimulation of svmpathetic nerves and subsequent increased NE release occurs 97 due to local metabolic changes in the myocardium as well as decreases in blood pressure and cardiac output. During early ischemia, increased re-uptake of NE into the nerve ending (uptake-1) can successfully prevent local NE accumulation in the myocardium.
However, as the ischemic episode progresses, the intact sodium gradient across the cell membrane necessary for this re-uptake is gradually lost, and excessive NE will start to accumulate (Schömig et al. 1984) . After even longer duration of ischemia, ATP-depletion of the nerve terminals occurs and exocytotic NE release will cease. Instead, after about 10 minutes of ischemia, local non-exocytotic norepinephrine release is responsible for the observed massive amounts of NE accumulated in the ischemic myocardium. Here, a two-step release mechanism is thought to occur (Schömig 1990) , comprising NE loss from the storage vesicles and consequent increased axoplasmic NE concentrations, followed by a carrier-mediated outward transport of NE into the synaptic cleft ( Figure   IB ). For this purpose, the uptakc-1 carrier is used in reverse mode, the altered sodium gradient across the neuronal membrane enabling binding of NE to the carrier and transportation to the extracellular space (Schömig et al. 1985) . This release is independent of extracellular calcium concentrations and is completely prevented by the presence of glucose (Dart et al. 1987) . Non-exocytotic release during ischemia can lead to extracellular NE-concentrations in the micromolar range (1000-fold increase) (Wilde et al. 1988 ) with potentially harmful consequences for the ischemic heart such as increased myocardial damage (calcium overload) and increased propensity to ventricular arrhvthmias.
Modulation of catecholamine release from the ischemic myocardium
Any intervention capable of reducing or preventing NE-release during myocardial ischemia has a potential beneficial effect. Many studies have focused on possible ways of modulating excessive NE-accumulation in the myocardium, often with apparent conflicting results. However, outcome depends on the dominant mechanism of NErelease present at the time of investigation (for review, see Schömig 1990) . For instance, during early ischemia, when exocytotic release is still predominant, blockade of the reuptake carrier by dcsipramine will result in an increase in NE-release. During longer periods of ischemia, non-exocytotic release using this carrier in the reverse direction will lead to decreased release. Also, stimulation of presynaptic adenosine-receptors will only influence exocytotic release and therefore will have no significant effect during longer periods of ischemia.Opening of neuronal KATP channels during ischemia has been suggested to be able to modulate NE-release in various tissues. Indeed, during simulated ischemia, KATP activation reduced the release of various neurotransmitters in brain tissue, whereas KATP inhibition aggravated its release (Amoroso et al. 1990 , Zini et al. 1993 
Figure 1. Schematic representations of exocytotic NE-release from sympathetic neurones during normal conditions (A), and non-cxocytotic NE-releasc during ischemia (B).
Schaeffer and Ladzdunski 1991). As suggested by Oe and colleagues, KATP channel activation may also attenuate NE release during myocardial ischemia, with potentially favorable impact on cardiac metabolism, ventricular arrhythmias and infarct size. Indeed, preliminary results from our laboratory show a significant decrease in release of NE by cromakalim in globally ischemic rabbit hearts as compared to control hearts (Remme et al. 1998 ).
In conclusion, these data on endogenous myocardial norepinephrine release (Oe et al. 1999 , Remme et al. 1998 provide alternative explanations for the many consequences of pharmacological KATP channel modulation.
